Articles From: Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy to PG&E Can Help Customers Save Money This Winter with a Home Upgrade


Pfizer Inc. (NYSE:PFE) announced today enrollment of the first patient in a multicenter Phase II clinical trial of the investigational compound PF-06252616 in boys with Duchenne muscular dystrophy (DMD), a genetic disorder characterized by progressive muscle degeneration and weakness.
Sign-up for Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy investment picks
2014/11/5
Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Group President, Vaccines, Oncology and Consumer Healthcare Business, at the Credit Suisse 2014 Healthcare Conference on Wednesday, November 12, 2014 at 8:00 a.m. Mountain Standard Time.
Sign-up for Pfizer Invites Public To Listen To Webcast Of Pfizer Discussion At Healthcare Conference investment picks
2014/12/16
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EST on Tuesday, January 27, 2015.
Sign-up for Pfizer Invites Public to View and Listen to Webcast of January 27 Conference Call with Analysts investment picks
2015/1/6
Pfizer Inc. invites investors and the general public to view and listen to a webcast of a presentation by Mikael Dolsten, President, Worldwide Research and Development, at the 33 rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2015 at 2:30 p.m. Pacific Standard Time.
Sign-up for Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference investment picks
The U.S. Food and Drug Administration (FDA) has informed Pfizer Inc. that at this time there is no plan for an Oncologic Drugs Advisory Committee meeting for IBRANCE ® (palbociclib). Pfizer continues to have an open and productive dialogue with the FDA as the application for IBRANCE advances.
Sign-up for Pfizer Provides Update on IBRANCE® (palbociclib) investment picks
Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of TRUMENBA ® (meningococcal group B vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B in individuals 10 through 25 years of age.
Sign-up for Pfizer Receives FDA Accelerated Approval for TRUMENBA® (Meningococcal Group B Vaccine) for the Prevention of Invasive Meningococcal B Disease in Adolescents and Young Adults investment picks
Pfizer Inc. (NYSE:PFE) reported financial results for third-quarter 2014.
Sign-up for PFIZER REPORTS THIRD-QUARTER 2014 RESULTS investment picks
Pfizer Inc. (NYSE:PFE) announced today top-line results from a double-blind Phase 3 study evaluating pregabalin controlled-release (CR) formulation in adult patients with postherpetic neuralgia (pain after shingles or PHN). The results show that pregabalin CR resulted in a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR) in pain reduction.
Sign-up for Pfizer Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Controlled-Release Formulation as a Treatment for Patients With Postherpetic Neuralgia investment picks
Pfizer shares (PFE) rose 1.4% in after-hours trade Thusday after the blue-chip drug maker said it has authorized a new $11 billion share buyback program, to be "utilized over time." That is in addition to the $1.3 billion left in its previous repurchase program.
Sign-up for Pfizer shares rise after new $11 billion share buyback program investment picks
Pfizer Inc. (NYSE: PFE ) has notified Pain Therapeutics, Inc. (NASDAQ: PTIE ) that it has decided to discontinue its agreement to develop and commercialize REMOXY™ (oxycodone) Extended-Release Capsules CII, an investigational extended-release oral formulation of oxycodone.
Sign-up for Pfizer to Discontinue Agreement on REMOXY™ (oxycodone) Extended-Release Capsules CII investment picks
By Natalia Drozdiak FRANKFURT --
Sign-up for Pfizer, Merck strike deal to develop cancer tumor treatment investment picks
By Angela Chen OPKO will get upfront payment of $295 million and is eligible for up to $275 million more Pfizer Inc. and OPKO Health Inc. have partnered to develop and commercialize an OPKO treatment for growth-hormone deficiency that could replace daily injections with weekly ones.
Sign-up for Pfizer, OPKO Health partner on growth-hormone treatment investment picks
2015/1/8
By Angela Chen The U.S. Food and Drug Administration isn't planning an advisory committee meeting at this time to evaluate Pfizer Inc.'s experimental breast-cancer treatment, despite the drug having received priority-review status in October, the company said Thursday.
Sign-up for Pfizer: FDA Not Planning Meeting Yet For Breast-Cancer Drug investment picks
Pfizer's stock (PFE) fell 1.6% in premarket trade Monday, after the blue-chip drug maker lowered its 2014 profit outlook following its agreement to team up with Germany's Merck KGaA to develop new cancer treatments.
Sign-up for Pfizer's stock drops after profit outlook cut investment picks
Pfizer Inc.'s stock (PFE) rose 1.8% in premarket trade Tuesday, after the drug giant reported better-than-expected third-quarter profit and sales.
Sign-up for Pfizer's stock rallies after earnings, sales beat expectations investment picks
Pfizer Inc. (NYSE:PFE) today announced the publication of a clinical study in the Journal of Clinical Psychiatry showing comparable sexual function in adult patients diagnosed with major depressive disorder (MDD) treated daily with PRISTIQ Extended Release Tablets 50mg and 100mg doses versus placebo.
Sign-up for Pfizer’s PRISTIQ® (desvenlafaxine) Demonstrates Low Potential For Sexual Dysfunction in Adults with Major Depressive Disorder investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1167748&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Expands India Operations and Reports Successful Holiday Season investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1160018&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Opens Two Additional European Sales Offices investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158170&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Reports Third Quarter 2014 Results investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1167095&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Responds to Unsolicited Investor Letter investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1156300&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Sets Third Quarter Conference Call for Wednesday, November 12, 2014 at 11:00 a.m. ET investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1158081&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb Supports Successful Inaugural Release of United States Mint's Kennedy Coin investment picks
http://media.marketwire.com/attachments/201409/276763_pfs.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1161555&ProfileId=051205&sourceType=1 ALLEN, TX --
Sign-up for PFSweb to Present at the 7th Annual LD Micro Conference on December 4, 2014 investment picks
Mellanox® Technologies, Ltd.
Sign-up for PFU LIMITED, a Fujitsu Company, Selects Mellanox Open Ethernet Switches for High-Definition Video Systems investment picks
SAN FRANCISCO , Dec.
Sign-up for PG&E and AIA Foundation Announce Winners of Zero Net Energy Design Competition investment picks
2015/1/5
As part of its ongoing dedication to education and powering California’s future, Pacific Gas and Electric Company (PG&E) today announced the launch of its fourth annual PG&E Bright Minds™ Scholarship program .
Sign-up for PG&E Announces Launch of 2015 Bright Minds™ Scholarship Program investment picks
MORE THAN 70 INVESTOR-OWNED ELECTRIC UTILITIES COMMIT TO INCREASING INVESTMENT IN CLEAN ELECTRIC VEHICLE FLEETS NATIONWIDE WASHINGTON , Nov.
Sign-up for PG&E Announces Two Major Electric Vehicle Initiatives At The White House With Senior Administration Officials investment picks
2014/12/9
39 Schools in Northern and Central California Receive Funding for Energy Projects SAN FRANCISCO , Dec.
Sign-up for PG&E Awards $250,000 In Bright Ideas Grants To California Schools investment picks
Pacific Gas and Electric Company (PG&E) today affirmed its commitment to transparency and accountability and encouraged the California Public Utilities Commission (CPUC) to adopt new protocols for open access to communications between the Commission and all parties who are interacting with the CPUC.
Sign-up for PG&E Backs Transparency and Accountability in Communications with the CPUC and Self-Reports Additional Emails that Could Reflect Past Violations of Rules investment picks
2014/11/17
SAN FRANCISCO , Nov.
Sign-up for PG&E Can Help Customers Save Money This Winter with a Home Upgrade investment picks
Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy to PG&E Can Help Customers Save Money This Winter with a Home Upgrade
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent